Shifting the paradigm of type 1 diabetes: a narrative review of disease modifying therapies

被引:0
|
作者
O'Donovan, Alexander J. [1 ]
Gorelik, Seth [1 ,2 ]
Nally, Laura M. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA
[2] Bowdoin Coll, Brunswick, ME USA
来源
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
关键词
type; 1; diabetes; stage; 2; 3; teplizumab; disease-modifying therapies; ANTI-CD3; MONOCLONAL-ANTIBODY; C-PEPTIDE RESPONSES; DOUBLE-BLIND; ONSET; TEPLIZUMAB; IDENTIFICATION; PATHOGENESIS; USTEKINUMAB; AUTOANTIGEN; INHIBITOR;
D O I
10.3389/fendo.2024.1477101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A new diagnosis of type 1 diabetes (T1D) may be accompanied by numerous lifelong financial, emotional, and physical challenges, thus advancements in therapies that can delay the onset of clinical disease are crucial. T1D is an autoimmune condition involving destruction of pancreatic beta cells leading to insulin deficiency, hyperglycemia, and long-term insulin dependence. The pathogenesis of T1D is classified into stages, with the first signal being the detection of autoantibodies without any glycemic changes. In the second stage, dysglycemia develops without symptoms, and in stage 3, symptoms of hyperglycemia become apparent, and at this time a clinical diagnosis of T1D is made. As a greater understanding of these stages of T1D have evolved, research efforts have been devoted to delaying the onset of clinical disease. To date, only one medication, teplizumab, has been approved by the Food and Drug Administration (FDA) for the treatment of stage 2 T1D. This narrative review present published trials and ongoing research on disease modifying therapies (DMT) in T1D, the mechanisms of action for each therapy, and the stages of T1D that these interventions are being studied.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies (vol 15, 1477101, 2024)
    O'Donovan, Alexander J.
    Gorelik, Seth
    Nally, Laura M.
    FRONTIERS IN ENDOCRINOLOGY, 2025, 15
  • [2] New therapeutic approaches for type 1 diabetes: Disease-modifying therapies
    Nagy, Geza
    Szekely, Tekla Evelin
    Somogyi, Aniko
    Herold, Magdolna
    Herold, Zoltan
    WORLD JOURNAL OF DIABETES, 2022, 13 (10) : 835 - 850
  • [3] Current perspectives and the future of disease-modifying therapies in type 1 diabetes
    Mondal, Sunetra
    Pappachan, Joseph M.
    WORLD JOURNAL OF DIABETES, 2025, 16 (01)
  • [4] The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: A systematic review and meta-analysis
    Lin, Chu
    Hu, Suiyuan
    Cai, Xiaoling
    Lv, Fang
    Yang, Wenjia
    Liu, Geling
    Yang, Xiaolin
    Ji, Linong
    PHARMACOLOGICAL RESEARCH, 2024, 203
  • [5] Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?
    Lord, Sandra
    Greenbaum, Carla J.
    PHARMACOLOGICAL RESEARCH, 2015, 98 : 3 - 8
  • [6] Biologic therapies in type 1 diabetes: how far are they from us?
    Deng Chao
    Xiang Yu-fei
    Zhou Zhi-guang
    CHINESE MEDICAL JOURNAL, 2013, 126 (21) : 4003 - 4005
  • [7] Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes
    Shapiro, Melanie R.
    Tallon, Erin M.
    Brown, Matthew E.
    Posgai, Amanda L.
    Clements, Mark A.
    Brusko, Todd M.
    DIABETOLOGIA, 2025, 68 (03) : 477 - 494
  • [8] Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review
    Felton, Jamie L.
    Griffin, Kurt J.
    Oram, Richard A.
    Speake, Cate
    Long, S. Alice
    Onengut-Gumuscu, Suna
    Rich, Stephen S.
    Monaco, Gabriela S. F.
    Evans-Molina, Carmella
    DiMeglio, Linda A.
    Ismail, Heba M.
    Steck, Andrea K.
    Dabelea, Dana
    Johnson, Randi K.
    Urazbayeva, Marzhan
    Gitelman, Stephen
    Wentworth, John M.
    Redondo, Maria J.
    Sims, Emily K.
    COMMUNICATIONS MEDICINE, 2023, 3 (01):
  • [9] Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes
    Greenbaum, Carla
    Lord, Sandra
    VanBuecken, Dana
    CURRENT DIABETES REPORTS, 2017, 17 (11)
  • [10] The shifting paradigm of a "cure" for type 1 diabetes: is technology replacing immune-based therapies?
    Pettus, Jeremy
    Von Herrath, Matthias
    ACTA DIABETOLOGICA, 2018, 55 (02) : 117 - 120